Results 151 to 160 of about 174,072,709 (188)

Soluble Suppression of Tumorigenicity 2: A Role in BiomarkerGuided Therapy of Heart Failure

Journal of Cardiology and Therapy, 2019
Alexander E. Berezin, Alexander A. Berezin   +1 more
openaire   +2 more sources

A Simple and Cost-Effective Electrochemical Assay for Heart Failure Prognosis Using Soluble Suppression of Tumorigenicity 2‑Specific Nanobodies. [PDF]

ACS Pharmacol Transl Sci
Sirimanakul S, Hurley JD, Vutipow N, Loison F, Kasorn A, Tabtimmai L, Riangrungroj P, Leelawattanachai J, Ananwattanasuk T, Swainson N, Choowongkomon K, Kruse AC, Waraho-Zhmayev D.   +12 more
europepmc   +1 more source

Dual and context-dependent role of the interleukin-33/soluble suppression of tumorigenicity 2 axis in obesity and adipose tissue inflammation. [PDF]

Mol Med
Casado M, Gómez-Ambrosi J, Ramírez B, Becerril S, Rodríguez A, Valentí V, Moncada R, Silva C, Escalada J, Frühbeck G, Catalán V.   +10 more
europepmc   +1 more source

Impact of Midregional N-Terminal Pro-Atrial Natriuretic Peptide and Soluble Suppression of Tumorigenicity 2 Levels on Heart Rhythm in Patients Treated With Catheter Ablation for Atrial Fibrillation: The Biorhythm Study. [PDF]

J Am Heart Assoc, 2021
Badoz M, Serzian G, Favoulet B, Sellal JM, De Chillou C, Hammache N, Laurent G, Mebazaa A, Ecarnot F, Bardonnet K, Seronde MF, Schiele F, Meneveau N.   +12 more
europepmc   +1 more source

Soluble Suppression of Tumorigenicity 2 (sST2) as a Diagnostic and Prognostic Marker in Acute Heart Failure and Sepsis: A Comparative Analysis. [PDF]

Diagnostics (Basel)
Davini F, Fogolari M, D'Avanzo G, Ristori MV, Nucciarelli S, Bani L, Cristiano A, De Cesaris M, Spoto S, Angeletti S.   +9 more
europepmc   +1 more source

Establishment of Reference Intervals for Soluble Suppression of Tumorigenicity 2 in the Elderly South Korean Population

Journal of Laboratory Medicine and Quality Assurance, 2023
Misuk Ji, Eunsin Bae, Youn Mi Choi
openaire   +1 more source

Reference interval and the role of soluble suppression of tumorigenicity 2 (sST2) in subclinical cardiac dysfunction at health checkups. [PDF]

J Clin Lab Anal, 2020
Nah EH, Cho S, Kim S, Cho HI.
europepmc   +1 more source

The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis. [PDF]

PLoS One, 2020
Liu N, Hang T, Gao X, Yang W, Kong W, Lou Q, Yang J.   +6 more
europepmc   +1 more source

Association of soluble suppression of tumorigenicity 2 with mortality and adverse outcomes in chronic kidney disease: a systematic review and meta-analysis. [PDF]

Clin Exp Nephrol
Bellos I, Marinaki S, Lagiou P, Benetou V.   +3 more
europepmc   +1 more source

The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery. [PDF]

Cardiovasc Diabetol, 2020
Demyanets S, Kaun C, Kaider A, Speidl W, Prager M, Oravec S, Hohensinner P, Wojta J, Rega-Kaun G.   +8 more
europepmc   +1 more source